VCs give the gift of capital; 2014 was a banner year for start-ups
09 January 2015
Merry Christmas, happy Hanukkah, joyous Kwanzaa. Whatever you celebrated, the venture capitalists gave the biopharma industry a mighty large gift in 2014. Investments in private drug companies tracked by BioWorld Snapshots rounded out the year at $3.85 billion, up substantially from the $2.6 billion in 2013 in the U.S.
Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory
08 January 2015
Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human Services’ (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license.
08 January 2015
Kyowa Hakko Kirin Co., Ltd. and Syndax Pharmaceuticals, Inc., today jointly announced that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea. Entinostat is a Class I selective histone deacetylase (HDAC) inhibitor being developed by Syndax in the United States and Europe in combination with hormone therapy for advanced breast cancer and immune therapy combinations in solid tumors.
Marinus Pharmaceuticals Hires Dr. Albena Patroneva as Chief Medical Officer
07 January 2015
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that it has retained Albena Patroneva, MD as Chief Medical Officer. Dr. Patroneva brings close to 20 years of experience spanning across research, drug development, clinical, regulatory and commercialization activities focused in neurology with large pharmaceutical companies, including AstraZeneca, Wyeth and Takeda. As Chief Medical Officer, Dr. Patroneva will oversee Marinus's clinical programs in epilepsy and pediatric orphan indications with its neurosteroid, ganaxolone.
Med tech exits pick up in 2014, momentum to continue into 2015
07 January 2015
Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.
A record year for biotech inspires some great expectations for 2015
07 January 2015
Life science-related IPOs rocketed from an anemic 11 in 2012 to 37 in 2013 and a red-hot 79 in 2014, reports Jonathan Norris, a managing director at Silicon Valley Bank, in his annual assessment of the life sciences industry's appetite for new deals.
Biopharma posts a chart-topping 41 new drug approvals in 2014
07 January 2015
A burst of new drug approvals at the FDA just before Christmas pushed the total to 41 for 2014, the fastest pace in the past 18 years and a fresh sign that at least a few of the lead players have learned how to efficiently target new therapies for development.
NHS England picks 100,000 Genomes Project sites ahead of February start date
07 January 2015
NHS England has selected the 11 centers that will form the backbone of the 100,000 Genomes Project. Each of the centers will begin recruiting patients with cancer and rare diseases on Feb. 2 and send the samples they gather to Illumina ($ILMN) for sequencing and analysis.
Analytics and Big Data investments spur bumper year for digital health funding
07 January 2015
The likelihood of 2014 being another high-water mark for digital health was clear from the first few months of the year. When digital health seed funder Rock Health tallied up the total last week, it found digital health companies raised $4.1 billion in 2014, almost as much as they pulled in across the three prior years combined.
FDA hits the highest level of drug approvals in 18 years
06 January 2015
The FDA cleared 41 new medications in 2014, the highest level for the agency since 1996, when a record 53 new products were approved. The total was also 14 more than the number of drugs the agency approved in 2013.
06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024